Comparative Pharmacology
Head-to-head clinical analysis: CARBOCAINE versus LARYNGOTRACHEAL ANESTHESIA KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBOCAINE versus LARYNGOTRACHEAL ANESTHESIA KIT.
CARBOCAINE vs LARYNGOTRACHEAL ANESTHESIA KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mepivacaine, the active ingredient in Carbocaine, is an amide-type local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting the initiation and conduction of nerve impulses.
Lidocaine and tetracaine are sodium channel blockers, inhibiting nerve impulse conduction, providing local anesthesia. Epinephrine is a vasoconstrictor that reduces systemic absorption and prolongs duration.
1% to 2% solution, 5-20 mL local infiltration or nerve block; maximum dose 400 mg (or 7 mg/kg) per 90-minute period.
4 mL of 4% lidocaine (160 mg) via atomizer or nebulizer for topical laryngotracheal anesthesia, with additional 2 mL aliquots as needed, not to exceed 4.5 mg/kg total dose.
None Documented
None Documented
2.0–3.5 hours in adults; prolonged in patients with hepatic impairment (up to 8–10 hours) or renal dysfunction.
Lidocaine terminal half-life: 1.5–2 hours (normal hepatic function); prolonged to 3–5 hours in heart failure or hepatic disease. Tetracaine: 2–3 hours.
Renal excretion of unchanged drug and metabolites accounts for approximately 95% of elimination, with less than 5% excreted in feces via biliary elimination.
Renal excretion of lidocaine and its metabolites (primarily monoethylglycinexylidide (MEGX) and glycinexylidide (GX)); <10% unchanged. Biliary/fecal excretion minimal (<5%).
Category C
Category C
Local Anesthetic
Local Anesthetic